<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346540</url>
  </required_header>
  <id_info>
    <org_study_id>1199.82</org_study_id>
    <secondary_id>2010-019707-32</secondary_id>
    <nct_id>NCT01346540</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.</brief_title>
  <official_title>LUME-Lung 3: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The LUME-Lung3 study is in 2 parts:

      Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that
      can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and
      cisplatin.

      Phase II - Placebo controlled efficacy study of BIBF 1120 added to standard 3 weekly cycles
      of gemcitabine and cisplatin therapy in patients with at least Stable Disease after 2
      previous courses of the chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2011</start_date>
  <completion_date type="Actual">January 17, 2017</completion_date>
  <primary_completion_date type="Actual">April 25, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Determination of Maximum Tolerated Dose (MTD) of BIBF 1120 added to cisplatin/gemcitabine based on the occurrence of DLTs during treatment cycle 1.</measure>
    <time_frame>up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Progression Free Survival.</measure>
    <time_frame>up to 55 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Realtionship of tumour size to clinical response.</measure>
    <time_frame>up to 55 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Evaluation of objective response.</measure>
    <time_frame>up to 55 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Survival</measure>
    <time_frame>up to 55 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Evalualuation of best overall tumour response.</measure>
    <time_frame>up to 55 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Incidence of adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00</measure>
    <time_frame>up to 55 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>BIBF 1120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGF inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BIBF 1120 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <description>VEGF inhibitor</description>
    <arm_group_label>BIBF 1120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BIBF 1120 placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Run-in Phase I

          1. Histologically or cytologically confirmed diagnosis of stage IIIB/IV or recurrent Non
             Small Cell Lung Cancer (NSCLC) with squamous cell histology.

          2. Measurable disease according to Response Evaluation Criteria in Solid Tumours ( RECIST
             1.1).

          3. Patient Eastern Cooperative Oncology Group (ECOG) score of 0-1.

          4. Male or female patients age = 18 years.

          5. Life expectancy of at least three (3) months.

          6. Written informed consent in accordance with International Conference on Harmonisation
             - Good Clinical Practice (ICH-GCP) guidelines.

             Phase II - in addition to the above criteria:

          7. Radiologically-confirmed at least stable disease after 2 prior cycles of cisplatin /
             gemcitabine chemotherapy.

        Exclusion criteria:

          1. Prior therapy for advanced or metastatic or recurrent Non Small Cell Lung Cancer
             (NSCLC). One prior adjuvant, neoadjuvant or adjuvant + neoadjuvant treatment is
             allowed if at least 12 months have elapsed between the end of the treatment and
             randomization

          2. Prior treatment with other Vascular Endothelial Growth Factor Receptor (VEGFR)
             inhibitors (other than bevacizumab)

          3. Any contraindications for treatment with gemcitabine and/or cisplatin.

          4. Use of any investigational drug within 4 weeks of entering the 1199.82 study.

          5. History of major thrombotic or clinically relevant bleeding event in the past 6
             months.

          6. Significant cardiovascular diseases (i.e. hypertension not controlled by medication.

          7. Surgery within 4 weeks (except tumour biopsy) prior randomisation and incomplete wound
             healing.

          8. Active brain metastases

          9. Radiotherapy (except extremities) within 3 months prior to baseline imaging and
             radiotherapy for brain metastasis &lt; 4 weeks prior baseline imaging.

         10. Any other current malignancy or malignancy diagnosed within the past five (5) years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1199.82.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.82.3102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.82.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.82.3406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.82.3410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>MÃ¡laga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.82.4401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.82.4402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 23, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

